Disodium chromoglycate therapy in perennial rhinitis.
DSCG was tested on 38 patients with perennial rhinitis in the form of a nasal spray (2%)in a double-blind cross-over trial. Few of the investigated parameters in the whole material showed any significant preference of DSCG. A marked drug order effect was shown; in the group receiving placebo first, most of the clinical parameters assessed both by the clinician and the patient were better for DSCG. A therapeutical trial with DSCG is worth trying in perennial rhinitis.
D000281:Administration, Intranasal; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D010919:Placebos; D004205:Cromolyn Sodium